Date: 2017-04-04
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Galapagos (Belgium) Gilead Sciences (USA - CA)
Product: filgotinib
Action mechanism: janus kinase inhibitor. Filgotinib is an orally-available, novel Janus kinase (JAK) inhibitor with selectivity for JAK1 developed by Galapagos. JAKs are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in rheumatoid arthritis patients. JAK inhibitors have shown long-term efficacy in rheumatoid arthritis studies with an early onset of action. Filgotinib differentiates from other JAK inhibitors in development by specifically targeting JAK1, a strategy which could result in a better efficacy and safety profile. Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications.
Disease: Sjögren's syndrome
Therapeutic area: Autoimmune diseases - Ophtalmological diseases
Country:
Trial details:
Latest news: • On April 4, 2017, Galapagos announced a new Phase 2 Proof-of-Concept study investigating filgotinib in Sjögren's syndrome. The Sjögren's study is being led by filgotinib collaboration partner Gilead Sciences.
